Most cited papers from Celerion (United States)

Celerion (United States)

What are the most cited papers from Celerion (United States)?

The most cited paper from Celerion (United States) is "Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial" (Adam L. Boxer et al., 2014), with 300 citations. Next come "Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor" (228) and "Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects" (154).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 33 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Adam L. Boxer et al. · The Lancet Neurology Open access	26 May 2014	300
2	Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor Jeanne Mendell, Hamim Zahir, Nobuko Matsushima et al. · American Journal of Cardiovascular Drugs Open access	19 Jun 2013	228
3	Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects Nobuko Matsushima, Frank Lee, Toshiyuki Sato et al. · Clinical Pharmacology in Drug Development	9 Sep 2013	154
4	Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A Thomayant Prueksaritanont, DA Tatosian, Xiaoyan Chu et al. · Clinical Pharmacology & Therapeutics	10 Dec 2016	144
5	A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers Grant C. O’Connell, John D. Pritchard, Chris Prue et al. · Internal and Emergency Medicine Open access	2 Feb 2019	114
6	A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers Kenneth M. Attie, Mark J. Allison, Ty McClure et al. · American Journal of Hematology Open access	9 Apr 2014	110
7	Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals Alexandra Elisabeth Schneider, Lucas Neas, Don W Graff et al. · Particle and Fibre Toxicology Open access	2010	102
8	First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody Pascal Espié, Yanling He, Phillip J. Koo et al. · American Journal of Transplantation Open access	24 Oct 2019	94
9	Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease Sabina Paglialunga, Clayton A. Dehn · Lipids in Health and Disease Open access	17 Sep 2016	93
10	Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy Daniel Rooks, Didier Laurent, Jens Præstgaard et al. · Journal of Cachexia Sarcopenia and Muscle Open access	14 Sep 2017	91
11	Recommendations On: Internal Standard Criteria, Stability, Incurred Sample Reanalysis and Recent 483s by the Global CRO Council for Bioanalysis Steve Lowes et al. · Bioanalysis	Jun 2011	89
12	QT Assessment in Early Drug Development: The Long and the Short of It Robert M. Lester, Sabina Paglialunga, Ian Johnson · International Journal of Molecular Sciences Open access	15 Mar 2019	82
13	Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies Sumit Kar, Sabina Paglialunga, M. Rafiqul Islam · The Journal of Clinical Pharmacology	18 May 2018	77
14	Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir Ellen G. J. Hulskotte, Hwa-ping Feng, Fengjuan Xuan et al. · Clinical Infectious Diseases	15 Nov 2012	77
15	Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK Linh Thuy Nguyen, Jaymes S. Holland, Dale Miles et al. · The Journal of Clinical Pharmacology	9 Apr 2015	77
16	Measurement of cardiovascular and pulmonary function endpoints and other physiological effects following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers Carl D. D’Ruiz, Grant C. O’Connell, Donald W. Graff et al. · Regulatory Toxicology and Pharmacology Open access	2 May 2017	75
17	Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects Linh Thuy Nguyen, Jaymes S. Holland, Richard D. Mamelok et al. · The Journal of Clinical Pharmacology	22 Apr 2015	75
18	2013 White Paper on Recent Issues in Bioanalysis: ‘ Hybrid ’ – The Best of LBA and LCMS Lauren F. Stevenson et al. · Bioanalysis	10 Oct 2013	75
19	Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers Grant C. O’Connell, Donald W. Graff, Carl D. D’Ruiz · Toxicology Mechanisms and Methods Open access	12 Jul 2016	74
20	2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 3 – Lba, Biomarkers and Immunogenicity) Lakshmi S. Amaravadi et al. · Bioanalysis Open access	Dec 2015	74
21	2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines & Biomarker Assay Performance (Part 3 – Lba: Immunogenicity, Biomarkers and PK Assays) Shalini Gupta et al. · Bioanalysis Open access	Dec 2017	69
22	A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants Fady I. Malik, Laura A Robertson, Danielle R. Armas et al. · JACC Basic to Translational Science Open access	Aug 2022	68
23	A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults Antonios O. Aliprantis, Dennis G. Wolford, Luzelena Caro et al. · Clinical Pharmacology in Drug Development	30 Oct 2020	67
24	First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers Jonathan C. Fox, Jennifer L. Hellawell, Satish Rao et al. · Clinical Pharmacology in Drug Development Open access	6 Jun 2019	67
25	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes Carl D. D’Ruiz, Donald W. Graff, Edward Robinson · BMC Public Health Open access	11 Jul 2016	67
26	Locally acting ACE‐083 increases muscle volume in healthy volunteers Chad E. Glasser, Michael Gartner, Dawn M. Wilson et al. · Muscle & Nerve Open access	27 Feb 2018	64
27	Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability Mitchell F. Stiles, Leanne R. Campbell, Donald W. Graff et al. · Psychopharmacology Open access	20 Jun 2017	63
28	Recommendations on Biomarker Bioanalytical Method Validation By Gcc Richard Hougton et al. · Bioanalysis	Oct 2012	62
29	Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes Carl D. D’Ruiz, Donald W. Graff, Xiaoli Yan · BMC Public Health Open access	30 Sep 2015	61
30	Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis Benoît Tyl, Meriam Kabbaj, Sara M. Azzam et al. · The Journal of Clinical Pharmacology	4 Jun 2011	61
31	A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment Daniel A. Tatosian et al. · Clinical Pharmacology & Therapeutics	24 Jul 2020	57
32	Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials Carine Beysen, Patricia E. Schroeder, Eric L. Wu et al. · Diabetes Obesity and Metabolism Open access	2 Dec 2020	55
33	Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer Ignacio Durán, Joan Carles, Iurie Bulat et al. · Clinical Pharmacokinetics Open access	27 Apr 2020	55
34	2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays) Lauren F. Stevenson et al. · Bioanalysis	29 Nov 2018	55
35	Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults Linh Thuy Nguyen, Natacha Benrimoh, Yuli Xie et al. · Anti-Cancer Drugs	3 May 2016	53
36	A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic Jeffrey J. Buda, F. Ivy Carroll, Thomas R. Kosten et al. · Neuropsychopharmacology Open access	23 Jan 2015	52
37	A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects Joanne M. Donovan, Michael Zimmer, Elliot M. Offman et al. · The Journal of Clinical Pharmacology Open access	11 Jan 2017	51
38	The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor Jeanne Mendell, Frank X. Lee, Shuquan Chen et al. · Journal of Cardiovascular Pharmacology	24 Apr 2013	50
39	Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus Eric G. Vajda, Douglas K. Logan, Kenneth C. Lasseter et al. · Diabetes Obesity and Metabolism Open access	8 Aug 2016	49
40	2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV) (Part 1 – Small Molecules, Peptides and Small Molecule Biomarkers by LCMS) Eric Yang et al. · Bioanalysis Open access	7 Oct 2016	48
41	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials Jee Bang, Iryna V. Lobach, Anthony E. Lang et al. · Parkinsonism & Related Disorders Open access	21 Apr 2016	48
42	The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects Ka Lai Yee, Sauzanne G. Khalilieh, Rosa I. Sánchez et al. · Clinical Drug Investigation	28 Mar 2017	46
43	Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants Wendy Ankrom, Jialin Xu, Marie‐Helene Vallee et al. · The Journal of Clinical Pharmacology Open access	16 Apr 2020	45
44	Recommendations on The Interpretation of The New European Medicines Agency Guideline on Bioanalytical Method Validation By Global Cro Council For Bioanalysis (Gcc) Mark Boterman et al. · Bioanalysis	Mar 2012	45
45	Five-Day Changes in Biomarkers of Exposure Among Adult Smokers After Completely Switching From Combustible Cigarettes to a Nicotine-Salt Pod System J. Bennett Jay, Erika L. Pfaunmiller, Norman Huang et al. · Nicotine & Tobacco Research Open access	31 Oct 2019	44
46	Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α‐synuclein Iddo Magen, Regina Ostritsky, Franziska Richter et al. · Pharmacology Research & Perspectives Open access	6 Aug 2014	44
47	2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 2 – Hybrid LBA/LCMS and Input from Regulatory Agencies) An Song et al. · Bioanalysis Open access	18 Nov 2016	43
48	Update on ICH E14/S7B Cardiac Safety Regulations: The Expanded Role of Preclinical Assays and the “Double‐Negative” Scenario Robert M. Lester · Clinical Pharmacology in Drug Development Open access	31 Jul 2021	42
49	2017 White Paper on Recent Issues in Bioanalysis: Aren’t Bmv Guidance/Guidelines ‘ Scientific ’? (Part 1 – LCMS: Small Molecules, Peptides and Small Molecule Biomarkers) Jan Welink et al. · Bioanalysis Open access	Nov 2017	41
50	Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum Mitchell F. Stiles, Leanne R. Campbell, Tao Jin et al. · Psychopharmacology Open access	3 May 2018	39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.